76691-35-5

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule. In this case, the compound has 10 carbon (C), 9 hydrogen (H), 1 fluorine (F), and 2 oxygen (O) atoms.
2. Derivative of 1,3-butanedione

Explanation

1,3-Butanedione, 1-(3-fluorophenyl)is derived from 1,3-butanedione, which is a diketone with two carbonyl groups.
3. 3-Fluorophenyl group

Explanation

The addition of a 3-fluorophenyl group to the 1 position of the butanedione molecule differentiates 1,3-Butanedione, 1-(3-fluorophenyl)- from its parent compound, 1,3-butanedione.
4. Chemical and pharmaceutical applications

Explanation

The compound is used in various chemical and pharmaceutical applications, although more specific information is needed to understand its full potential.
5. Building block in organic synthesis

Explanation

Due to its structure, 1,3-Butanedione, 1-(3-fluorophenyl)- may serve as a building block in the synthesis of more complex organic molecules.
6. Pharmaceutical intermediate

Explanation

It may be used as an intermediate in the development of new drugs, contributing to the formation of the final pharmaceutical product.
7. Research and industrial processes

Explanation

The compound may have specific properties or interactions that make it useful in certain research or industrial processes, although further information is required to determine its exact applications.
8. Potential uses

Explanation

The compound's potential uses are not fully understood and would require more information about its properties and interactions to determine its suitability for specific applications.

Upstream product

• 451-02-5 ethyl 3-fluorobenzoate 
• 67-64-1 acetone 
• 456-48-4 3-Fluorobenzaldehyde 
• 141-78-6 ethyl acetate 
• 455-36-7 1-(3-fluorophenyl)ethanone 

Downstream Products

• 76691-05-9 (E)-1-(3-Fluoro-phenyl)-3-(4-phenyl-piperazin-1-yl)-but-2-en-1-one 
• 76691-09-3 (E)-1-(3-Fluoro-phenyl)-3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-but-2-en-1-one 
• 910025-64-8 C₁₈H₁₅FN₂O₂S 
• 1411690-90-8 1-(3-fluorophenyl)-3-(phenylamino)-but-2-en-1-one 
• 76691-08-2 (E)-1-(3-Fluoro-phenyl)-3-[4-(4-fluoro-phenyl)-piperazin-1-yl]-but-2-en-1-one 
• 76691-06-0 (E)-1-(3-Fluoro-phenyl)-3-piperidin-1-yl-but-2-en-1-one 

Relevant academic research and scientific papers

I2-Promoted [3+2] Cyclization of 1,3-Diketones with Potassium Thiocyanate: a Route to Thiazol-2(3H)-One Derivatives

An I2-promoted strategy has been developed for the synthesis of thiazol-2(3H)-one derivatives from 1,3-diketones with potassium thiocyanate. This [3+2] cyclization reaction involves C?S and C?N bond formation and exhibits good functional group tolerance. A series of thiazol-2(3H)-one derivatives are obtained in moderate to good yields. (Figure presented.).

Direct synthesis of 1,3-dicarbonyl compounds via radical coupling of aldehydes with ketones under metal-free conditions

An efficient approach for the synthesis of 1,3-diketones from aldehydes and ketones has been developed using Bu4NI (TBAI) as the catalyst. In the presence of DTBP-TBHP/p-TsOH, aldehydes undergo radical coupling with ketones to provide the desired products in moderate to high yields at 120 °C. Although various substituents on the aromatic ring of aldehydes are well tolerable under the standard reaction conditions, the protocol is limited by the scope of ketones. The method exhibits advantages in terms of the easy access of the starting materials, operational simplicity, functional group tolerance, and the absence of metal catalyst.

Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors

Current treatment for hepatitis C is barely satisfactory, there is an urgent need to develop novel agents for combating hepatitis C virus infection. This study discovered a new class of thieno[2,3-b]pyridine derivatives as HCV inhibitors. First, a hit compound characterized by a thienopyridine core was identified in a cell-based screening of our privileged small molecule library. And then, structure activity relationship study of the hit compound led to the discovery of several potent compounds without obvious cytotoxicity in vitro (12c, EC50 = 3.3 μM, SI >30.3, 12b, EC50 = 3.5 μM, SI >28.6, 10l, EC50 = 3.9 μM, SI >25.6, 12o, EC 50 = 4.5 μM, SI >22.2, respectively). Although the mechanism of them had not been clearly elucidated, our preliminary optimization of this class of compounds had provided us a start point to develop new anti-HCV agents.

Synthesis of iridium and ruthenium complexes with (N,N), (N,O) and (O,O) coordinating bidentate ligands as potential anti-cancer agents

Several Ru-arene and Ir-Cp* complexes have been prepared incorporating (N,N), (N,O) and (O,O) coordinating bidentate ligands and have been found to be active against both HT-29 and MCF-7 cell lines. By incorporating a biologically active ligand into a metal complex the anti-cancer activity is increased.

Synthesis of 5-acyl-3,4-dihydropyrimidine-2-thiones via solvent-free, solution-phase and solid-phase Biginelli procedures

Compounds belonging to the 5-acyl-3,4-dihydropyrimidine-2-thione family were obtained using a solvent-free Biginelli condensation with or without the use of a catalyst. An unprecedented solid-phase procedure involving a polymer-supported aldehyde allowed